HANSOH PHARMAC. HD-00001 (3KY) - Total Liabilities
Based on the latest financial reports, HANSOH PHARMAC. HD-00001 (3KY) has total liabilities worth €4.54 Billion EUR (≈ $5.30 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See HANSOH PHARMAC. HD-00001 (3KY) defensive interval to measure how many days the company can operate on defensive assets alone.
HANSOH PHARMAC. HD-00001 - Total Liabilities Trend (2021–2025)
This chart illustrates how HANSOH PHARMAC. HD-00001's total liabilities have evolved over time, based on quarterly financial data. Check HANSOH PHARMAC. HD-00001 (3KY) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
HANSOH PHARMAC. HD-00001 Competitors by Total Liabilities
The table below lists competitors of HANSOH PHARMAC. HD-00001 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Loews Corp
NYSE:L
|
USA | $67.20 Billion |
|
Sany Heavy Industry Co Ltd
SHG:600031
|
China | CN¥82.76 Billion |
|
Pure Storage Inc
NYSE:PSTG
|
USA | $2.82 Billion |
|
Erste Bank Polska S.A.
WAR:EBP
|
Poland | zł268.62 Billion |
|
EnBW Energie Baden-Württemberg AG
XETRA:EBK
|
Germany | €46.35 Billion |
|
STD BK GRP SP.ADRS RC-10
F:SKCS
|
Germany | €3.31 Trillion |
|
Incyte Corporation
NASDAQ:INCY
|
USA | $1.53 Billion |
|
Bayan Resources Tbk
JK:BYAN
|
Indonesia | Rp10.00 Trillion |
Liability Composition Analysis (2021–2025)
This chart breaks down HANSOH PHARMAC. HD-00001's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see HANSOH PHARMAC. HD-00001 asset portfolio.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how HANSOH PHARMAC. HD-00001's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for HANSOH PHARMAC. HD-00001 (2021–2025)
The table below shows the annual total liabilities of HANSOH PHARMAC. HD-00001 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €4.54 Billion ≈ $5.30 Billion |
+52.32% |
| 2024-12-31 | €2.98 Billion ≈ $3.48 Billion |
-58.89% |
| 2023-12-31 | €7.24 Billion ≈ $8.47 Billion |
-1.50% |
| 2022-12-31 | €7.35 Billion ≈ $8.60 Billion |
+3.14% |
| 2021-12-31 | €7.13 Billion ≈ $8.34 Billion |
-- |
About HANSOH PHARMAC. HD-00001
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products … Read more